Description

What It Is

Tesamorelin is a modified growth hormone-releasing hormone (GHRH) analog. Unlike synthetic GH, it does not replace your hormones — it triggers a natural cascade, telling your pituitary to release its own growth hormone, which then signals your liver to produce IGF-1. FDA-approved in 2010 as Egrifta, it is one of the few peptides with real human clinical data behind it.

Key Research Areas

• Visceral Fat Reduction — Clinical trials show ~15-18% reduction in deep belly fat at 26 weeks, without the same effect on subcutaneous fat
• Natural GH Pulse — Works with your pituitary-liver axis for physiological hormone release, not synthetic replacement
• IGF-1 Response — Increases IGF-1 levels via your own endogenous pathway
• Metabolic Markers — Studies report improvements in triglycerides and adipose tissue inflammation markers
• Cognitive Studies — Early research exploring effects on memory and cognitive function in older adults

How Users Typically Run It

Daily subcutaneous administration. Protocols generally run 12-26 weeks to align with clinical study durations. Best administered in the morning or before bed on an empty stomach.

The Cascade

Tesamorelin injection → Pituitary receives signal → GH released (pulsatile) → Liver produces IGF-1. Your own pituitary. Your own GH. Natural pulse.

Research Disclaimer

For research and educational purposes only. Not medical advice. FDA-approved indication is specific to HIV-lipodystrophy. Consult a qualified professional before use.